Emerging Microbes and Infections (Dec 2024)

ZMapp reduces diffusion of Ebola viral particles in fresh human cervicovaginal mucus

  • Alison Schaefer,
  • Bing Yang,
  • Holly A. Schroeder,
  • Dimple Harit,
  • Mike S. Humphry,
  • Larry Zeitlin,
  • Kevin J. Whaley,
  • Jacques Ravel,
  • William A. Fischer,
  • Samuel K. Lai

DOI
https://doi.org/10.1080/22221751.2024.2352520
Journal volume & issue
Vol. 13, no. 1

Abstract

Read online

ABSTRACTVaginal transmission from semen of male Ebola virus (EBOV) survivors has been implicated as a potential origin of Ebola virus disease (EVD) outbreaks. While EBOV in semen must traverse cervicovaginal mucus (CVM) to reach target cells, the behaviour of EBOV in CVM is poorly understood. CVM contains substantial quantities of IgG, and arrays of IgG bound to a virion can develop multiple Fc-mucin bonds, immobilizing the IgG/virion complex in mucus. Here, we measured the real-time mobility of fluorescent Ebola virus-like-particles (VLP) in 50 CVM specimens from 17 women, with and without ZMapp, a cocktail of 3 monoclonal IgGs against EBOV. ZMapp-mediated effective trapping of Ebola VLPs in CVM from a subset of women across the menstrual cycle, primarily those with Lactobacillus crispatus dominant microbiota. Our work underscores the influence of the vaginal microbiome on IgG-mucin crosslinking against EBOV and identifies bottlenecks in the sexual transmission of EBOV.

Keywords